Download Free Medical Hormonal Contraceptives-Considerations for Women with HIV and AIDS PowerPoint Presentation

Hormonal Contraceptives-Considerations for Women with HIV and AIDS PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation titled ""Hormonal Contraceptives – Considerations for Women with HIV and AIDS"" describes considerations for women with HIV and AIDS.

Tags : Contraceptive Care, HIV, Human Immunodeficiency Virus, HIV, infection, cells, immune system, AIDS, Acquired Immune Deficiency Syndrome, HIV Positive, hormonal contraception, antiretroviral treatment, Contraception, women, woman, pregnancy, Combined oral contraceptive pills, COCs, Progestin-only oral contraceptive pills, POPs, Injectables, Depo-Provera/DMPA, Implants, Norplant, Jadelle, Sinoplant, Implanon, STIs

Published on : Apr 23, 2021 | Views : 2615 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Hormonal Contraceptives – Considerations for Women with HIV and AIDS
Slide 2-

Hormonal Contraceptives Combined oral contraceptive pills (COCs) Progestin-only oral contraceptive pills (POPs) Injectables (Depo-Provera/DMPA) Implants (Norplant, Jadelle, Sinoplant, Implanon)
Slide 3-

Hormonal Contraceptive Methods: Appropriate for Women with HIV Very effective Easy to use Suitable for short- or long-term use Reversible Non-contraceptive health benefits Serious complications extremely rare
Slide 4-

Overview: Theoretical Concerns about Hormonal Methods For women with HIV: ARVs may reduce method effectiveness or increase side effects Contraceptives may affect ARV efficacy Hormonal methods may possibly affect infectivity disease progression Future research may lead to changes in clinical practices. Source: Leitz, 2000; Piscitelli, 1996.
Slide 5-

How ARVs Interact with COCs May cause an increase or decrease of hormone levels Some ARVs speed up liver metabolism and could lower blood levels of contraceptive hormones, may reduce method effectiveness Not all ARV classes interact with contraceptive hormones (e.g., NRTIs)
Slide 6-

Interactions between COCs and PIs Source: WHO, 2004; Ouellet, 1998.
Slide 7-

Interactions between COCs and NNRTIs teratogen Source: WHO, 2004; Cohn, 2005. No significant interaction was found between ARV drugs and progestin-only injectables particularly DMPA.
Slide 8-

Clinical Significance of COC/ARV Interaction Is Unknown Studies examining clinical outcomes are needed (i.e., pregnancy rates, ovulation indicators) No data on interaction between ARVs and hormonal contraceptives other than COCs and DMPA Ritonavir-boosted protease inhibitors reduce contraceptive hormone blood levels considerably not generally recommended for women on oral contraceptives or combined injectables not part of first-line ARV regimens
Slide 9-

Hormonal Contraceptive Use: Increases Risk of Cervical Infection Source: Lavreys, 2004. * not statistically significant when adjusted for demographic factors
Slide 10-

Hormonal Contraceptive Use: May Increase HIV Shedding HIV shedding may increase risk of HIV transmission to partner In one study, modest increase in cervical shedding of HIV-infected cells but no free virus Impact on infectivity is uncertain Source: Wang, 1999; Wang, 2004; John, 2001.
Slide 11-

Relationships Require Further Research Future research may lead to changes in clinical practices. Source: McClelland, 2001; Ghys, 1997.
Slide 12-

Future research may lead to changes in clinical practices. Hormonal Contraceptive Use: Theoretically May Affect Disease Progression Use of hormonal contraceptives near the time of HIV acquisition is associated with: Higher viral load set point (indicator of disease progression) Infection with multiple subtypes of HIV, resulting in faster CD4 decline Source: Lavreys, 2004; Sagar, 2003. Viral load increases after initial infection Immune system’s killer cells respond Viral load is reduced Higher set point Lower set point
Slide 13-

Hormonal Contraceptive Use and HIV: What Providers Should Do Counsel clients that certain ARV drugs reduce blood levels of contraceptive hormones which in theory may reduce method effectiveness (except DMPA) Encourage clients to tell providers which drugs they are taking When there is a choice, prescribe ARV drugs that do not interact with hormonal methods Encourage correct and consistent use of contraceptive method Keep abreast of guideline updates